Sage Therapeutics
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.
Recently announced topline results from a Phase II study show SAGE-324, Sage Therapeutics’ investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, significantly reduced tremor score in adult patients with essential tremor.
On Wednesday, Sage Therapeutics and Samsung Biologics announced that they had found just that in their new chief executive officers.
Sage and Biogen forged the deal to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.
Following a setback with its experimental major depressive disorder drug in December, Sage Therapeutics will initiate a corporate restructuring that includes halving its employee headcount in order to focus its resources on the development of its pipeline.
It was, as usual, a pretty busy week in clinical trial news. Here’s a look.
The Phase III failure was certainly a setback for the company as it chased Janssen and its Esketamine-based treatment Spravato for MDD.
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
The company is working to break into the broader depression market with SAGE-217. The company discussed its pipeline at its “FutureCast.”
JOBS
IN THE PRESS